Rate My Professor Tania Slatter

Slatter's research centers on molecular and experimental pathology and translational medicine, specializing in cancer, perinatal medicine, and autoimmune disease. Her clinical interests encompass brain cancer, breast cancer, laboratory medicine, chronic kidney disease, macular degeneration, and perinatal pathology. Notable projects include elucidating the Δ133p53 isoform's role in promoting tumour growth via TLR4 enhancement; developing diagnostic tests for personalized cancer therapies; establishing the Otago Placental Study to examine DNA damage and HPV effects on pregnancy outcomes; and exploring telomere maintenance mechanisms in glioblastomas and uterine cancers as part of the New Zealand Brain Tumour Study. Co-directing the Slatter and Hung Laboratory for Molecular Pathogenesis, her work advances prognostic biomarkers and novel treatments. Key publications comprise Δ133p53 isoform enhances TLR4 function to promote tumour growth (Carcinogenesis, 2025), Lithium-induced kidney injury and fibrosis: A versatile model to explore cellular pathways of injury and repair (Physiological Reports, 2025), Adaptive homeostasis and the p53 isoform network (EMBO Reports, 2021), and TP53 splice mutations have tumour-independent effects on genomic stability and prognosis (International Journal of Molecular Sciences, 2025). With over 1,200 citations, her contributions significantly impact oncology, histopathology, and diagnostic advancements.